In a study by Zhou et al., ablation of the 1α-hydroxylase gene led to hypertension, cardiac hypertrophy, and systolic dysfunction, and this cardiac phenotype was rescued with exogenous 1,25dihydroxyvitamin D administration.
In 2007 the Nobel Committee honored Evans, Capecchi, and Smithies for their seminal contributions that led to the development of specific gene knockout (KO) mouse models. [1] [2] [3] This truly amazing technology has allowed countless investigators in all disciplines of medicine to manipulate their specific gene of choice and, by doing so, to uncover its biological function by examining the downstream consequences. In the nephrology community, we have not been without benefit, as this technology has led to a profound understanding of various diseases, including nephrotic syndrome, 4 renal tubular acidosis, 5 and polycystic kidney disease, 6 to name a few. In this process, novel therapeutic options have been uncovered. 7 Gene-targeted ablation has also allowed us to appreciate the downstream consequences of altered vitamin D metabolism in which the kidney plays an intimate role. 8, 9 Classic experiments performed during the 1970s in nephrectomized animals demonstrated that the kidney is the primary organ responsible for converting the circulating form of vitamin D, 25-hydroxyvitamin D (25(OH)D 3 ), to the hormonal form of vitamin D, 1,25-dihydroxyvitamin D (1,25(OH) 2 D 3 ), a process that is tightly regulated. 10 The renal mitochondrial 1α-hydroxylase (CYP27B1) enzyme was cloned and extensively studied as a primary cause of inherited rickets. 11 Subsequently, autocrine production of 1,25(OH) 2 D 3 was documented in several other cell types, including skin, brain, placenta, and circulating cells such as macrophages, all of which were subsequently found to express 1α-hydroxylase activity. 11 This enzyme was successfully knocked out by Goltzman and others, 8 and the downstream consequences -focusing on mineral and bone effects -included hypocalcemia, hyperparathyroidism, and skeletal abnormalities. These in vivo alterations mimic those classically described in patients with chronic renal failure. 11 The renal enzyme is primarily expressed in the proximal tubule and is regulated by 1,25(OH) 2 D 3 , phosphorus, and parathyroid hormone, the first two inhibiting its activity and the third stimulating its activity. 12 Recently, regulation by fibroblast growth factor-23 has also been uncovered. 11 Although all four appear to regulate kidney 1α-hydroxylase activity, it is likely that 1α-hydroxylase activity outside the kidney is not regulated by all of these same factors.
Zhou et al. 13 (this issue) have now demonstrated in a series of elegant experiments that a defect in the 1α-hydroxylase gene and the lack of 1,25(OH) 2 D 3 in vivo lead to the cardiac phenotype of hypertension, left ventricular and cardiomyocyte hypertrophy, and impaired systolic function, and that this phenotype was not rescued by normalization of ambient calcium or phosphorus levels but was rescued by replacement with the hormone 1,25(OH) 2 D 3 . Furthermore, marked elevation of renal renin and angiotensinogen expression and protein levels, and corresponding findings in the plasma, including plasma aldosterone levels, were also normalized by 1,25(OH) 2 D 3 administration. Cardiac renin mRNA and protein levels were markedly elevated in 1α-hydroxylase KO compared with wildtype animals, and both were nearly normalized by 1,25(OH) 2 D 3 administration. Real-time polymerase chain reaction with reverse transcription demonstrated the presence of both the vitamin D receptor (VDR) and 1α-hydroxylase in cardiac tissue of wild-type animals, and, as expected, only VDR in 1α-hydroxylase KO animals. Thus, although local cardiac conversion of 25(OH)D 3 to 1,25(OH) 2 D 3 may be important, the 1α-hydroxylase KO model distinctly demonstrated that exogenous 1,25(OH) 2 D 3 rescued the cardiac phenotype in animals without a functional 1α-hydroxylase enzyme.
Cardiac alterations were also normalized after treatment with an angiotensinconverting enzyme inhibitor or an angiotensin II receptor antagonist, suggesting that the effect of 1,25(OH) 2 D 3 on the heart may be mediated through the renin-angiotensin system (RAS). In both the 1,25(OH) 2 D 3 -treated and the RAS inhibitor-treated animals, blood pressure was reduced; thus blood pressure reduction also may have contributed to the observed cardioprotective effects. It would have been interesting to examine 1α-hydroxylase KO animals treated with an antihypertensive agent known not to affect the RAS to determine whether the cardioprotective effects were primarily linked to the local RAS. In animals treated with RAS inhibitors, commentar y however, renal renin expression was elevated, whereas animals treated with 1,25(OH) 2 D 3 demonstrated suppressed renal renin expression. Zhou and colleagues 13 concluded that 1,25(OH) 2 D 3 regulates cardiac RAS and, via this mechanism, confers cardioprotection.
As with all in vivo or clinical observations, corroborative studies strengthen the biological relevance of any finding. At least two previously described in vivo models of altered vitamin D metabolism complement the findings of Zhou et al. 13 First, gene-targeted ablation of the vitamin D receptor -the VDR KO mouse model -demonstrated elevated blood pressure, cardiac and cardiomyocyte hypertrophy, and increased cardiac renin expression. 14, 15 Second, we recently demonstrated that activated vitamin D sterol administered to the Dahl salt-sensitive rat significantly attenuated the progression of cardiac hypertrophy and improved the functional, molecular, biochemical, and genetic cardiac parameters otherwise altered in this reliable animal model of cardiac abnormalities (Figure 1 ). 16 We documented that the Dahl salt-sensitive rat also becomes profoundly 25(OH)D 3 deficient, which had been reported in the past. Cardiac improvements were independent of blood pressure, as therapy did not significantly reduce blood pressure. Cardiac-specific renin expression was markedly attenuated with vitamin D sterol treatment; this is similar to the results published by Zhou et al. 13 Thus, multiple lines of evidence support the concept that 1,25(OH) 2 D 3 has a cardiovascular protective effect, and that this effect requires ligand-bound VDR activation. Whether 1,25(OH) 2 D 3 acts directly or indirectly (for example, via renal-or vascular-mediated benefits) on the heart, or via genomic or nongenomic mechanisms, remains unsettled. Future efforts, including those examining the cardiac effects of 1,25(OH) 2 D 3 in uremic models, conditional cardiac-specific VDR KO models, and models testing acute nongenomic versus less acute genomic effects, will better delineate the precise mechanisms of action and their relevance to patients with and without renal disease.
Patients with renal failure demonstrate profound 25(OH)D 3 deficiency, which has been recently associated with subsequent adverse cardiovascular outcomes in patients with 17 and without 18 overt kidney disease. In addition, as renal failure progresses, renal 1α-hydroxylase activity is suppressed; hence circulating levels of the active hormone 1,25(OH) 2 D 3 are also markedly lowered. 17 While patients with kidney disease may have VDR polymorphisms that lead to altered ligand binding or altered post-binding signaling, the 1α-hydroxylase KO model provides mechanistic insights that link 1,25(OH) 2 D 3 deficiency -which is quite prevalent in patients with renal failure -with the virtually ubiquitous cardiac structural and functional alterations present in this population.
In vivo effects of 1,25(OH) 2 D 3 on the heart appear to be independent of serum calcium and phosphorus levels, which is consistent with our own human observational studies suggesting that therapy with 1,25(OH) 2 D 3 or its analogues is associated with a reduction in cardiovascular-related mortality independent of serum calcium and phosphorus levels. 19, 20 Human correlations exist, as children with rickets with cardiomyopathy and cardiac hypertrophy markedly improve after therapy with vitamin D; 21 however, detailed studies in patients with renal disease are currently lacking. Therefore, as fundamental efforts to define the mechanisms linking vitamin D sterols to cardiovascular benefits forge ahead, the existing data support the need to proceed with human studies testing whether various formulations of vitamin D have a cardioprotective effect, and whether they are safe to administer for this indication. The VDR KO, Dahl salt-sensitive, and 1α-hydroxylase KO models of altered vitamin D metabolism, combined with suggestive observational studies, have now converged -as they ideally should -into prospective clinical studies (for example, the PRIMO and PRIMO II studies (ClinicalTrials.gov studies NCT00497146 22 and NCT00616902 23 ) that will test whether the cardiac effects of vitamin D sterols successfully translate from exquisite in vivo models to actually change patient outcomes.
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The author would like to thank Michael Holick Patients with chronic kidney disease (CKD) suffer from cachexia, which is characterized by muscle wasting, loss of protein stores, a low serum albumin, anorexia, and increased energy expenditures. This maladaptive response is further exacerbated by an inability to effectively utilize dietary nutrients. As a consequence, mortality is substantially increased, and treatment strategies to combat this response have been only partially successful. A study by Cheung et al. 1 (this issue) provides some insight into how these central features of cachexia may be intertwined.
Elevated circulating levels of cytokines are frequently observed in uremic cachexia. Recent evidence indicates that cytokines can modify the release and/or function of neurotransmitters, thereby altering appetite. Leptin, which is secreted by adipocytes, is a member of the interleukin-6 family of cytokines. It communicates with the hypothalamus to decrease appetite and results in decreased food intake and an increase in energy expenditure. 2 In fact, administration of leptin induces anorexia in mice. 3 The level of leptin is increased in the presence of overfeeding, insulin, glucocorticoids, and angiotensin II and is decreased with fasting, testosterone, thyroid, and cold exposure. 4 Leptin acts to regulate appetite through the melanocortin signaling pathway (Figure 1 ). Cheung and colleagues have previously used both gene deletion and pharmacologic approaches
